


**Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Original) A compound of the formula I, or a salt, solvate, or a physiologically functional derivative thereof




I

in which


M is a radical of the formula



,




, or




;

Y is a radical of the formula



or



; and


R1, R2 and R3 are independently hydrogen, -NH<sub>2</sub>, halogen, -OC<sub>1-6</sub> alkyl, -CF<sub>3</sub>, -N(C=O)CH<sub>3</sub>, -(C=O)OH, -CF<sub>3</sub>, -(C=O)NH<sub>2</sub>, -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>OH, or -C<sub>1-6</sub>alkyl;

W is -(CH<sub>2</sub>)<sub>n</sub>-, in which n is 0 to 2; and



R4 is -NH<sub>2</sub>, or -OH; and

R5 and R6 are independently hydrogen or halogen.

2. (Original) A compound of Formula I of claim 1 in which M is a radical of the formula



Y is a radical of the formula



in which R2 is hydrogen, -NH<sub>2</sub>, halogen, -OC<sub>1-6</sub>alkyl, -CF<sub>3</sub>, -N(C=O)CH<sub>3</sub>, -(C=O)OH, -CF<sub>3</sub>, -(C=O)NH<sub>2</sub>, -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>OH, or -C<sub>1-6</sub>alkyl.

3. (Original) A method of inhibiting hYAK3 and/or CK2 in a mammal; comprising, administering to the mammal a therapeutically effective amount of a

compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

4. (Original) A pharmaceutical composition including a therapeutically effective amount of a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

5. (Original) A method of treating or preventing diseases of the erythroid and hematopoietic systems selected from the group consisting of: neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity, HIV or cancer, and drug-induced anemias; and myelosuppression; comprising administering to a mammal a therapeutically effective amount of a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

6. (Original) A method of treating or preventing cancer or viral infections; comprising administering to a mammal a therapeutically effective amount of a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

7. (Currently Amended) A compound of formula I of ~~any of claim 1, 3, 4, 5, or 6~~ claim 1 selected from the group consisting of  
4-anilino-5-carboxyl-2-(4-methoxyphenyl)thiazole;  
4-anilino-5-methoxycarbonyl-2-(4-methoxyphenyl) thiazole;  
5-aminocarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;  
5-methoxycarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino) thiazole;  
5-carboxyl-2-(4-methoxyphenyl)-4-(2-trifluoromethyl)anilinothiazole;  
5-aminocarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;  
5-carboxyl-4-(3-fluoroanilino)-2-(4-methoxyphenyl)thiazole;  
5-carboxyl-2-(4-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;;  
4-anilino-5-carboxyl-2-(3-methoxyphenyl)thiazole;  
5-carboxyl-4-(2-fluoroanilino)-2-(3-methoxyphenyl)thiazole;

4-benzylamino-5-methoxycarboxyl 2-(4-methoxyphenyl)thiazole  
4-(2-chloro-phenylamino)-2-(2,3-dihydro-benzofuran-5-yl)-thiazole-5-carboxylic acid ethyl ester;  
4-(2-chlorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic acid;  
4-(2-chlorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic acid amide;  
4-(2-chloro-5-fluorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic acid amide;  
4-(2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(5-acetylamino-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(5-carbamoyl-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(2-chloro-5-sulfophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(5-amino-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(2-chloro-4-methanesulfonylphenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(4-carboxy-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;  
4-(2-chlorophenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;  
4-(3,5-dichloropyridin-4-ylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;  
2-pyridin-3-yl-4-(pyridin-3-ylamino)-thiazole-5-carboxylic acid;  
4-(2-chlorophenylamino)-2-(pyridin-4-yl)-thiazole-5-carboxylic acid;  
4-[2-(3-chlorophenyl) ethylamino]-2-(pyridin-4-yl) thiazole-5-carboxylic acid;  
4-[2-(3-chlorophenyl) ethylamino]-2-(pyridin-4-yl)-thiazole-5-carboxylic acid amide;  
4-(2-chloro-5-fluorophenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;  
4-(2-chloro-5-fluoro-phenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid amide;  
2-(pyridin-3-yl)-4-(2-trifluoromethyl-phenylamino) thiazole-5-carboxylic acid amide;  
4-(4-chlorobenzylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid; and  
4-(4-chlorobenzylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid.